How Big Will the SpaceX IPO Be?
Operated up to now as a private business, SpaceX will…
Sell
49
CVAC Quote, Financials, Valuation and Earnings
Last price:
$4.66
Seasonality move
:
-15.44%
Day range:
$4.66 - $4.66
52-week range:
$2.48 - $5.72
Dividend yield:
0%
P/E ratio:
6.52x
P/S ratio:
12.94x
P/B ratio:
1.03x
Volume:
--
Avg. volume:
240.5K
1-year change:
24.93%
Market cap:
$1B
Revenue:
$578.9M
EPS (TTM):
$0.71
Analysts' Opinion
-
Consensus RatingCureVac NV has received a consensus rating of Hold. The company's average rating is a Hold based on 1 Buy rating, 3 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $5.31, CureVac NV has an estimated upside of 14.28% from its current price of $4.66.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $4.97 representing 100% downside risk from its current price of $4.66.
Fair Value
-
According to the consensus of 4 analysts, CureVac NV has 14.28% upside to fair value with a price target of $5.31 per share.
CVAC vs. S&P 500
-
Over the past 5 trading days, CureVac NV has overperformed the S&P 500 by 0.1% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
CureVac NV does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
CureVac NV revenues have been falling on a year-over-year basis for 4 quarters in a row. In the most recent quarter CureVac NV reported revenues of $63.3M.
Earnings Growth
-
CureVac NV earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter CureVac NV reported earnings per share of $1.41.
Enterprise value:
601.6M
EV / Invested capital:
--
Price / LTM sales:
12.94x
EV / EBIT:
3.12x
EV / Revenue:
7.42x
PEG ratio (5yr expected):
0.21x
EV / Free cash flow:
-4.18x
Price / Operating cash flow:
6.00x
Enterprise value / EBITDA:
2.87x
Gross Profit (TTM):
$52.6M
Return On Assets:
17.11%
Net Income Margin (TTM):
35.46%
Return On Equity:
20.55%
Return On Invested Capital:
19.52%
Operating Margin:
-18.33%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $45.8M | $595.8M | $81M | $542.6M | $63.3M | |
| Gross Profit | -$132M | $403.8M | $52.6M | $515.2M | $57.9M | |
| Operating Income | -$330.5M | $180M | -$193.7M | $443.5M | -$11.6M | |
| EBITDA | -$307.5M | $206.3M | -$170.7M | $448M | -$6.7M | |
| Diluted EPS | -$1.53 | $0.54 | $0.71 | $1.65 | $1.41 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $1.7B | $609.6M | $568.4M | $652.6M | $1B | |
| Total Assets | $1.9B | $892M | $892.1M | $953.3M | $1.3B | |
| Current Liabilities | $943.5M | $168.8M | $159.5M | $105.3M | $277.5M | |
| Total Liabilities | $1.1B | $279.7M | $254.4M | $144.5M | $314.2M | |
| Total Equity | $805.8M | $612.3M | $637.6M | $808.8M | $1B | |
| Total Debt | $65.5M | $40.4M | $44.6M | $44.8M | $41.2M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$297.2M | $140.9M | -$139M | $384.9M | $32M | |
| Cash From Investing | -$66.7M | -$32.4M | -$5M | -$3.9M | -$447K | |
| Cash From Financing | $287.1M | -$8.6M | -$5.8M | -$1.7M | -$1.6M | |
| Free Cash Flow | -$363.6M | $108.5M | -$144M | $381M | $31.6M | |
CVAC
Sector
Market Cap
$1B
$23.4M
Price % of 52-Week High
81.47%
48.49%
Dividend Yield
0%
0%
Shareholder Yield
0.01%
-1.67%
1-Year Price Total Return
24.93%
-23.18%
Beta (5-Year)
1.877
0.504
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$4.66
200-day SMA
Sell
Level
$4.96
Bollinger Bands (100)
Sell
Level
4.65 - 5.41
Chaikin Money Flow
Sell
Level
--
20-day SMA
Sell
Level
$4.66
Relative Strength Index (RSI14)
Sell
Level
47.96
ADX Line
Neutral
Level
Williams %R
Sell
Level
-5.2632
50-day SMA
Sell
Level
$4.73
MACD (12, 26)
Buy
Level
1.27
25-day Aroon Oscillator
Sell
Level
0
On Balance Volume
Neutral
Level
--
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (3.9683)
Buy
CA Score
(Annual)
Level (2.1508)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (8)
Buy
Ohlson Score
Level (-7.8964)
Buy
Piotroski F Score
(Annual)
Level (8)
Buy
Quality Ratio Score
Level (4)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Stock Forecast FAQ
In the current month, CVAC has received 1 Buy ratings 3 Hold ratings, and 0 Sell ratings. The CVAC average analyst price target in the past 3 months is $5.31.
-
Where Will CureVac NV Stock Be In 1 Year?
According to analysts, the consensus estimate is that CureVac NV share price will rise to $5.31 per share over the next 12 months.
-
What Do Analysts Say About CureVac NV?
Analysts are divided on their view about CureVac NV share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that CureVac NV is a Sell and believe this share price will drop from its current level to $4.97.
-
What Is CureVac NV's Price Target?
The price target for CureVac NV over the next 1-year time period is forecast to be $5.31 according to 4 Wall Street analysts, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 3 analysts rate the stock a Hold.
-
Is CVAC A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for CureVac NV is a Hold. 3 of 4 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of CVAC?
You can purchase shares of CureVac NV via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase CureVac NV shares.
-
What Is The CureVac NV Share Price Today?
CureVac NV was last trading at $4.66 per share. This represents the most recent stock quote for CureVac NV. Yesterday, CureVac NV closed at $4.66 per share.
-
How To Buy CureVac NV Stock Online?
In order to purchase CureVac NV stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get CVAC Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
CVAC
Sector
P/E ratio
6.52x
23.40x
PEG ratio
0.21x
-0.01x
P/B ratio
1.03x
1.74x
Price / LTM sales
12.94x
1.48x
Growth Metrics
CVAC
Sector
Revenue growth
-88.34%
3.36%
Earnings growth
-14.25%
9.35%
Revenue (5-year growth)
97.04%
6.22%
Earnings forecast
-$0.11
-$0.19
Profitability
CVAC
Sector
Profitability FY 2024
$443.4M
$2.7M
Return on invested capital
19.52%
-33.62%
Return on assets
17.11%
-29.68%
Return on equity
20.55%
-38.98%
Earnings Date
Last Earnings Date
Nov
12
Next Earnings Date
Apr
9
Estimated Next Earnings Date
Feb
11
Balance Sheet
CVAC
Sector
Total cash
$488.9M
$25M
Short term investments
$3.8M
$23.9M
Total assets
$831.3M
$72.5M
Long term debt
$41.2M
$2.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will ISRG Stock Be in 5 Years?
Intuitive Surgical (NASDAQ:ISRG) is the innovative medical tech business behind…
Is Kratos Stock a Good Investment?
UAV and hypersonic system defense contractor Kratos (NASDAQ:KTOS) has swung…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
53
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 30x
Alerts
Sell
40
BILL alert for Feb 7
Bill Holdings, Inc. [BILL] is up 37.11% over the past day.
Buy
75
PRLB alert for Feb 7
Proto Labs, Inc. [PRLB] is up 28.33% over the past day.
Sell
30
MSTR alert for Feb 7
Strategy, Inc. [MSTR] is up 26.08% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
